Advitech announces highlights and financial results for third quarter 2007



    TSX VENTURE EXCHANGE: AVI

    QUEBEC CITY, Nov. 29 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Company") (TSX Venture Exchange: AVI) today announced its 2007 third quarter
highlights and financial results.
    During the third quarter of 2007, Advitech's revenues from Dermylex(TM)
sales have continued to increase and significant progress has been made to
expand our products portfolio with the announcement of positive preclinical
results in wound healing.

    
    HIGHLIGHTS OF THIRD QUARTER
    -------------------------------------------------------------------------

    - Third quarter revenues reached $377,000, a 38% increase over the
      previous 2007 quarter. The increase resulted from a 20% increase in
      Dermylex(TM) sales, and from non-recurring royalty revenue. Compared to
      the third quarter of 2006, revenues increased by 27%. The increase is
      mainly the result of Dermylex(TM) sales. The Company expects continued
      growth for the final quarter of 2007.
    - Dermylex(TM) is now available in the U.S. under the BioDerm brand name,
      in France under the Psopax brand name and in Canada (Dermylex(TM)). We
      plan to sign two additional marketing and distribution agreements in
      the fourth quarter of 2007.
    - Positive preclinical results for a new wound healing application for
      XP-828L technology platform were announced. Wound healing is a large
      market. Biological wound-healing products generate, according to
      Kalorama Information, $350 million in revenue worldwide, with a 27%
      annual growth rate for five years. An initial product release is
      planned during 2008.
    - Advitech revealed new efficacy results from a post-marketing study that
      shows that using Dermylex(TM) with topical corticosteroids and
      vitamin D analogs can create a synergistic effect and improve overall
      treatment efficacy. The main study's findings were the subject of a
      scientific publication in October.
    - The Company granted Diversified Natural Products (DNP) an exclusive
      worldwide license for the development and commercialization of the IBD
      application of our XP-828L technology platform. We elected to focus our
      energy on derma related applications only.

    FINANCIAL RESULTS
    -------------------------------------------------------------------------

    Third quarter ended September 30, 2007:

    - Third quarter revenues reached $377,000, a 38% increase over the
      previous 2007 quarter. The increase resulted from a 20% increase in
      Dermylex(TM) sales, and from non-recurring royalty revenue. Compared to
      the third quarter of 2006, revenues increased by 27%. The increase is
      mainly the result of Dermylex(TM) sales. The Company expects continued
      growth for the final quarter of 2007.
    - Net loss was $302,000, compared to $266,000 for the third quarter of
      2006, an increase of 13%, mostly driven by higher administrative
      expenses and by higher financial expenses related to the new financing.
    - As at September 30, 2007, the Company had $1.6 million cash on hand,
      compared to $1.9 million as at June 30, 2007, a decrease of $273,000
      which results from third quarter operating activities.

    Nine-month period ended September 30, 2007:

    - Revenues increased by 51% to $ 705,000 compared to $ 465,000 for the
      corresponding period of 2006. The increase results from Dermylex(TM)
      sales growth arising from new American and French territories.
    - Net loss was $1,209,000 or $0.02 per share, compared to $987,000, or
      $0.02 per share, for the corresponding period of 2006, an increase of
      23% which is mainly the result of the cost related to the completion of
      the Company's funding plan and the research and development expenses
      related to the XP-828L technology platform development program.

    "Financial and corporate results for the third quarter of 2007 are in line
with the Company's plan and respect the guidelines of our business model"
stated Mr. Renaud Beauchesne, CEO and President of Advitech Inc. He added that
"revenue from sales of Dermylex(TM) is growing at a steady pace in accordance
with our plan for fiscal 2007."
    "We are proud of the scientific goals reached through the quarter" stated
Ms. Christina Juneau, Ph. D., Vice-President, Research and Development. "I am
very excited about the preclinical results on wound healing. A new application
in this field would open an access to an important market" added Ms. Juneau.

                       Selected financial information
             (In thousands of dollars, except per share amounts)

                                Three-month period         Nine-month period
                                ended September 30,       ended September 30,
                                 2007         2006         2007         2006
                           (unaudited)  (unaudited)  (unaudited)  (unaudited)
    ---------------------- ------------------------ -------------------------
    Financial Results
    Total Revenues          $   377.5    $   298.1    $   704.6    $   465.3
    Operating Expenses      $   679.5    $   564.5    $ 1,914.0    $ 1,452.5
    Research and
     Development Costs,
     net of Tax             $    85.4    $   103.9    $   333.8    $   299.3
    Credits and Grants
    Net Loss                $  (302.0)   $  (266.4)   $(1,209.4)   $  (987.2)
    Loss per Share,
     Basic and Diluted      $     0.0    $     0.0    $   (0.02)   $   (0.02)


                                                          As at        As at
                                                   September 30, December 31,
                                                           2007         2006
                                                     (unaudited)    (Audited)
    ---------------------- ------------------------ -------------------------
    Balance Sheet
    Cash and Cash Equivalents                         $ 1,637.0    $   601.4
    Other Current Assets                              $   601.9    $   432.9
    Long-term Assets                                  $   185.9    $   202.7

    Current Liabilities                               $   503.4    $   515.1
    Long-term Liabilities                             $ 1,682.4    $ 1,092.4
    Shareholders' Equity                              $   239.0    $  (370.5)


    The third quarter financial statements as well as the management's
discussion and analysis of results of operations and financial condition, are
available on Sedar: http://www.sedar.com/.

    About Advitech Inc. www.advitech.com

    Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
Immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Recently, Advitech launched Dermylex(TM) for the treatment of
mild-to-moderate psoriasis.

    About Dermylex(TM) www.dermylex.com

    Dermylex(TM), developed by Advitech, is an oral natural health product
formulated to improve mild-to-moderate psoriasis symptoms. Two clinical
trials, including a 112-day, multi-center, double-blind, placebo-controlled
trial with 84 patients, clinically proved the efficacy and safety of
Dermylex(TM) for that type of psoriasis. Dermylex(TM) is currently available
in Canada and the U.S. (as BioDerm, Dermylex), and will soon be available in
France and Belgium (as Psopax(R)).

    This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein.

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.
    
    %SEDAR: 00021006EF




For further information:

For further information: Advitech Inc: Renaud Beauchesne, MBA, President
and Chief Executive Officer, (418) 686-7498 ext. 228, info@advitech.com; Serge
Comeau, Investor's relations, (514) 862-4160, s.comeau@advitech.com;
www.advitech.com

Organization Profile

ADVITECH INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890